Status and phase
Conditions
Treatments
About
The researchers are doing this study to look at the health outcomes of people with advanced ovarian cancer who have a second look laparoscopy (SLL) after they complete their first course of chemotherapy. The researchers will compare the health outcomes of people who have minimal residual disease (MRD-small amounts of cancer cells in the body after a person receives treatment) at the time of SLL with the health outcomes of people who do not have MRD at the time of SLL. The researchers are also doing this study to determine if SLL is safe and practical (feasible) in people with advanced ovarian cancer who have completed the first course of therapy for their disease.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients assigned female at birth≥ 18 years of age
Suspected or known stage III-IV epithelial ovarian cancer for which the patient has undergone, or is planned to undergo, attempted primary or interval debulking surgery
Homologous Recombination Deficiency testing should be planned to be completed prior to completion of initial platinum/taxane chemotherapy. HRD testing can be determined using :
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
80 participants in 1 patient group
Loading...
Central trial contact
Rachel Grisham, MD; Kara Long Roche, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal